I think the statement is generally good, but will likely lead to confusion with this bit which is given a prominent position as one of three quotes before the statement:
“The commercial opportunities and implications are also notable, not least for the pharmaceutical and financial services industries.”
If you read through the comments after the statement, they are all fine and welcome comments relevant to the guideline.
The last one, from Richard Ramyar, who is and economist not a clinician, includes the above quote and explains it further. I guess in that context it makes some sense, but to me it shouldn't be highlighted as one of 3 key points directly related to the guideline and its implementation. Doctors with ME have enough on their plates focusing on medical education and implementation. I don't think they have the resources or expertise to make sweeping statements about medico legal, insurance, commercial and industrial developments. With the possible exception of doing something about people like Sharpe and White in their role as advisors to health insurance companies.
I think it's a mistake for Doctors with ME to give a platform to an economist with a different agenda. There may be a place for a different organisation to be set up to investigate and advise on medico-legal, insurance, commercial, etc. aspects of ME. I'd rather DwME stuck to their area of expertise.
But I'm not a member or registered supporter of DwME. I recognise their right to run their organisation as they see fit, and wish them well.